<DOC>
	<DOCNO>NCT01471847</DOCNO>
	<brief_summary>This prospective , multi-center , open-label , phase Ib/ II study ( two part ) patient locally advance metastatic HER2+ breast cancer . The first part ( phase Ib ) investigate MTD/ RP2D combination therapy BEZ235 BID weekly trastuzumab use Bayesian model . Once MTD/ RP2D establish second part ( phase II ) start . Phase II evaluate efficacy safety weekly trastuzumab plus BEZ235 BID compare capecitabine lapatinib .</brief_summary>
	<brief_title>A Phase Ib/II Study BEZ235 Trastuzumab Patients With HER2-positive Breast Cancer Who Failed Prior Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patient female ≥ 18 year age Patient histologically and/or cytologically confirm diagnosis HER2positive invasive breast cancer inoperable locally advanced metastatic disease Patients control asymptomatic CNS metastasis eligible Patient adequate bone marrow organ function , recovery clinically significant toxicity relate prior antineoplastic therapy Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Hemoglobin ( Hgb ) ≥ 9.0 g/dL INR ≤ 2 Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x ULN ( ≤ 5.0 x ULN liver metastasis present ) Total serum bilirubin ≤ 1.5 x ULN ( patient know Gilbert Syndrome , total bilirubin ≤ 3.0 x ULN , direct bilirubin ≤ 1.5 x ULN ) Serum creatinine ≤ 1.5 x ULN Fasting plasma glucose ( FPG ) ≤ 140mg/dL [ 7.8 mmol/L ] HbA1c ≤ 8 % Patient receive prior trastuzumab ( alone combination ) NO 3 prior cytotoxic chemotherapy line Prior endocrine radiotherapy allow Patient ECOG performance status 02 ( Phase Ib ) 01 ( Phase II ) Additional inclusion criterion phase II : Available tumor tissue ( archival fresh ) biomarker analysis ; know PI3K activation status At least one measurable lesion per RECIST 1.1 Patient receive prior treatment taxane Patient `` trastuzumabresistance disease '' define : Recurrence trastuzumab ( TDM1 ) within 12 month since last infusion adjuvant set Progression within 4 week since last infusion trastuzumab ( TDM1 ) locally advanced metastatic set Previous treatment PI3K and/or mTOR inhibitor Symptomatic/uncontrolled Central Nervous System ( CNS ) metastases Concurrent malignancy malignancy last 3 year prior enrollment Wide field radiotherapy ≤ 28 day limit field radiation palliation ≤ 14 day prior start study drug Active cardiac disease ( e.g . LVEF less institutional low limit normal , QTcF &gt; 480 msec , unstable angina pectoris , ventricular , supraventricular nodal arrhythmia ) Inadequately control hypertension Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BEZ235 Treatment start study treatment drug know risk induce Torsades de Pointes , moderate strong inhibitor inducer isoenzyme CYP3A4 , warfarin coumadin analogue , LHRH agonists Intolerance contraindication trastuzumab treatment Pregnant nursing ( lactate ) woman Additional exclusion criterion phase II : Prior treatment capecitabine lapatinib Intolerance contraindication capecitabine lapatinib Previous treatment HER2 target agent trastuzumab TDM1 Peripheral neuropathy ≥ Grade 2</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Locally advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>breast cancer</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>PI3K</keyword>
	<keyword>mTOR</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>target therapy</keyword>
	<keyword>LABC</keyword>
	<keyword>MBC</keyword>
</DOC>